Breaking Bad Proteins—Discovery Approaches and the Road to Clinic for Degraders - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue (Article De Synthèse) Cells Année : 2024

Breaking Bad Proteins—Discovery Approaches and the Road to Clinic for Degraders

Résumé

Proteolysis-targeting chimeras (PROTACs) describe compounds that bind to and induce degradation of a target by simultaneously binding to a ubiquitin ligase. More generally referred to as bifunctional degraders, PROTACs have led the way in the field of targeted protein degradation (TPD), with several compounds currently undergoing clinical testing. Alongside bifunctional degraders, single-moiety compounds, or molecular glue degraders (MGDs), are increasingly being considered as a viable approach for development of therapeutics, driven by advances in rational discovery approaches. This review focuses on drug discovery with respect to bifunctional and molecular glue degraders within the ubiquitin proteasome system, including analysis of mechanistic concepts and discovery approaches, with an overview of current clinical and pre-clinical degrader status in oncology, neurodegenerative and inflammatory disease.
Fichier principal
Vignette du fichier
Bouvier, Breaking Bad Proteins, 2024.pdf (1.48 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Licence : CC BY - Paternité

Dates et versions

hal-04522952 , version 1 (27-03-2024)

Licence

Paternité

Identifiants

Citer

Corentin Bouvier, Rachel Lawrence, Francesca Cavallo, Wendy Xolalpa, Allan Jordan, et al.. Breaking Bad Proteins—Discovery Approaches and the Road to Clinic for Degraders. Cells, 2024, 13 (7), pp.578. ⟨10.3390/cells13070578⟩. ⟨hal-04522952⟩
1 Consultations
1 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More